Sugi Predict

Sugi Predict / Compounds / SCHEMBL204264

SCHEMBL204264

SCHEMBL204264

COC(=O)[C@@H]1CC(=O)CN1C(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 1/20 0.51
▸ ANPEP P15144 1/20 0.51
▸ MITF O75030 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.48
▸ FKBP1A P62942 1/20 0.46
▸ PSEN1 P49768 1/20 0.46
▸ PSEN2 P49810 1/20 0.46
▸ APH1B Q8WW43 1/20 0.46
▸ NCSTN Q92542 1/20 0.46
▸ APH1A Q96BI3 1/20 0.46
▸ PSENEN Q9NZ42 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ PREP P48147 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CYP19A1 P11511 1/20 0.45
▸ HTR2C P28335 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL204265 1.00 MMP2 (0.51) MMP2ANPEPMITFMAPTHTT
SCHEMBL8225741 1.00 MMP2 (0.51) MMP2ANPEPMITFMAPTHTT
SCHEMBL26945273 0.91 FKBP1A (0.49) NPSR1FKBP1APSEN1PSEN2APH1B
SCHEMBL8863318 0.91 FKBP1A (0.49) NPSR1FKBP1APSEN1PSEN2APH1B
SCHEMBL8863381 0.89 NPSR1 (0.48) NPSR1FKBP1APSEN1PSEN2APH1B
SCHEMBL8293214 0.89 NPSR1 (0.48) NPSR1FKBP1APSEN1PSEN2APH1B
SCHEMBL2126991 0.88 NPSR1 (0.49) MITFMAPTHTTNPSR1FKBP1A
SCHEMBL26310890 0.88 NPSR1 (0.49) MITFMAPTHTTNPSR1FKBP1A
SCHEMBL25344606 0.87 SMN1; SMN2 (0.50) NPSR1PSEN1PSEN2APH1BNCSTN
SCHEMBL4847560 0.87 SMN1; SMN2 (0.50) NPSR1PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149985-A1 METHODS OF PREPARING MELANOCORTIN 4 RECEPTOR AGONISTS LG CHEM, LTD. (KR) 2025-07-17 — — WO disclosed
WO-2025011610-A1 AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-16 — — WO disclosed
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 — — EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 — — CN disclosed
CN-108440507-B Compound as apoptosis protein inhibitor and application thereof 南京圣和药物研发有限公司 2022-10-18 — — CN disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 — — WO disclosed
EP-3699176-A2 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-08-26 — — EP disclosed
US-20200123132-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2020-04-23 — — US disclosed
US-10344019-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2019-07-09 — — US disclosed
US-10301260-B2 Pyrrolidine GPR40 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2019-05-28 — — US disclosed
EP-1361225-A1 COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS Sankyo Company, Limited (JP) 2003-11-12 — — EP disclosed
WO-2003062265-A2 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2003-07-31 — — WO disclosed
WO-2002057264-A1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES SANKYO COMPANY LIMITED (JP) 2002-07-25 — — WO disclosed
US-5631385-A Method for the preparation of N-substituted 4-ketoproline derivatives DEGUSSA AKTIENGESELLSCHAFT (DE) 1997-05-20 — — US disclosed
EP-0752419-A2 Process for the preparation of N-substituted 4-ketoproline derivatives Degussa Aktiengesellschaft (DE) 1997-01-08 — — EP disclosed
EP-0050800-B2 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them SCHERING CORP (US) 1995-06-07 — — EP disclosed
US-5348944-A Hypotensive agents SCHERING CORPORATION (US) 1994-09-20 — — US disclosed
EP-0050800-B1 CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1986-06-18 — — EP disclosed
US-4470972-A 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids SCHERING CORPORATION (US) 1984-09-11 — — US disclosed
EP-0050800-A1 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1982-05-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301260-B2 Pyrrolidine GPR40 modulators GPR55, GPR65, GPR4 MMP2 4628/4885ANPEP 3429/4885MITF 495/4885
US-10344019-B2 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 MMP2 3149/4885ANPEP 411/4885MITF 1783/4885
US-20200123132-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 MMP2 3149/4885ANPEP 411/4885MITF 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.